Tag Archives: liraglutide

Weight loss conversations often focus on a simple question: how much lean mass is preserved? However, emerging research suggests that the story is more complex. GLP-1 receptor agonists are well known for promoting weight loss and improving glycemic control, but scientists are increasingly examining how these medications influence muscle health …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity. However, one question clinicians increasingly ask is whether gastric motility adapts during long-term GLP-1 therapy. These medications slow gastric emptying, which contributes to appetite control and postprandial glucose reduction. Yet the human body often …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …

Dermatologic reactions linked to GLP-1 therapy are gaining attention as the use of glucagon-like peptide-1 receptor agonists continues to expand in diabetes and obesity care. While injection-site irritation is well recognized, clinicians are increasingly observing broader skin changes in patients treated with semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide …

Using GLP-1 therapy for lean type 2 diabetes challenges a long-standing assumption in diabetes care: that glucagon-like peptide-1 receptor agonists are primarily for patients with obesity. But what if body mass index is not the right guide for treatment decisions? Lean individuals with type 2 diabetes often exhibit insulin resistance, …

Can a medication designed to lower blood sugar also influence how the body handles iron? As research into the link between GLP-1 therapy and iron metabolism grows, scientists are beginning to explore how incretin signaling may intersect with inflammation, anemia, and iron regulation pathways. While GLP-1 receptor agonists are widely …

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

Inflammation sits at the heart of cardiometabolic disease. While GLP-1 receptor agonists are best known for improving glycemic control and supporting weight loss, emerging research suggests their role may extend further. Could the anti-inflammatory effects of GLP-1 therapies help explain some of the cardiovascular benefits observed in large outcome trials? …

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …